ecrin-mdr-crcClinical2020IPD Sharing (as of July 2022): No Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer’s data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.Carcinoma, Non-Small-Cell LungColorectal CancerColorectal NeoplasmsCachexiaWasting SyndromePancreatic CancerPancreatic NeoplasmsNon-Small-Cell Lung CancerColorectal CancerColorectal NeoplasmsCachexiaCarcinoma, Non-small-cell LungWasting SyndromePancreatic CancerNon-small-cell Lung CancerPancreatic NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2332372United States11Colorectal cancer, weight loss, anorexia, muscle loss, fatigueCachexia, non-small cell lung cancer, pancreatic cancerECRIN MDRCompletedfalseStudy to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.2020-11-152332372NCT04299048